Next Article in Journal
Quantitative Imaging of Gd Nanoparticles in Mice Using Benchtop Cone-Beam X-ray Fluorescence Computed Tomography System
Previous Article in Journal
Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies
Article

Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients

1
Medical Science Research Institute, Soonchunhyang University Seoul Hospital, Seoul 336-745, Korea
2
Department of Biochemistry, Soonchunhyang University College of Medicine, Cheonan 330-930, Korea
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(9), 2314; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20092314
Received: 29 March 2019 / Revised: 24 April 2019 / Accepted: 8 May 2019 / Published: 10 May 2019
(This article belongs to the Section Molecular Biology)
Mesenchymal stem cells (MSCs) are optimal sources of autologous stem cells for cell-based therapy in chronic kidney disease (CKD). However, CKD-associated pathophysiological conditions, such as endoplasmic reticulum (ER) stress and oxidative stress, decrease MSC function. In this work, we study the protective effect of pioglitazone on MSCs isolated from CKD patients (CKD-MSCs) against CKD-induced ER stress. In CKD-MSCs, ER stress is found to induce mitochondrial reactive oxygen species generation and mitochondrial dysfunction. Treatment with pioglitazone reduces the expression of ER stress markers and mitochondrial fusion proteins. Pioglitazone increases the expression of cellular prion protein (PrPC) in CKD-MSCs, which is dependent on the expression levels of proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). Treatment with pioglitazone is found to protect CKD-MSCs against reactive oxygen species generation, aberrant mitochondrial oxidative phosphorylation of complexes I and IV, and aberrant proliferation capacity through the PGC-1α-PrPC axis. These results indicate that pioglitazone protects the mitochondria of MSCs from CKD-induced ER stress. Pioglitazone treatment of CKD-MSCs may be a potential therapeutic strategy for CKD patients. View Full-Text
Keywords: cellular prion protein; chronic kidney disease; endoplasmic reticulum stress; mesenchymal stem cells; mitochondria; proliferator-activated receptor gamma coactivator 1-alpha cellular prion protein; chronic kidney disease; endoplasmic reticulum stress; mesenchymal stem cells; mitochondria; proliferator-activated receptor gamma coactivator 1-alpha
Show Figures

Figure 1

MDPI and ACS Style

Yoon, Y.M.; Lee, J.H.; Yun, C.W.; Lee, S.H. Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients. Int. J. Mol. Sci. 2019, 20, 2314. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20092314

AMA Style

Yoon YM, Lee JH, Yun CW, Lee SH. Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients. International Journal of Molecular Sciences. 2019; 20(9):2314. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20092314

Chicago/Turabian Style

Yoon, Yeo M., Jun H. Lee, Chul W. Yun, and Sang H. Lee 2019. "Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients" International Journal of Molecular Sciences 20, no. 9: 2314. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20092314

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop